New insider activity at Medpace Holdings ( (MEDP) ) has taken place on November 20, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CEO August J. Troendle recently made headlines by selling 31,053 shares of Medpace Holdings stock, a transaction valued at an impressive $18,376,704.
Recent Updates on MEDP stock
In the last 24 hours, Medpace Holdings has been the focus of several updates regarding its ongoing clinical studies, which could influence its stock performance. BMO Capital initiated coverage with a Market Perform rating, citing the stock’s full valuation amidst a “tepid” biotech funding environment and potential macroeconomic volatility. Key developments include Medpace’s collaboration with AVM Biotechnology on the OPAL Study for lymphoid malignancies, and a promising ARDS study targeting COVID-19 and influenza. Additionally, Medpace’s partnership with Telix Pharmaceuticals on a Phase 3 study for advanced kidney cancer, and with Radiopharm Theranostics on a study for metastatic solid tumors, highlight its strategic positioning in oncology. These collaborations and clinical advancements are significant as they may boost investor confidence and interest, potentially impacting Medpace’s stock positively.
Spark’s Take on MEDP Stock
According to Spark, TipRanks’ AI Analyst, MEDP is a Outperform.
Medpace Holdings demonstrates strong financial performance and positive earnings call sentiment, which are the most significant factors driving the score. Technical analysis indicates strong momentum but also suggests caution due to overbought conditions. The high P/E ratio impacts the valuation score, reflecting potential overvaluation concerns.
To see Spark’s full report on MEDP stock, click here.
More about Medpace Holdings
YTD Price Performance: 76.90%
Average Trading Volume: 313,454
Technical Sentiment Signal: Buy
Current Market Cap: $16.68B